Skip to main content

Real-world effects of beremagene geperpavec in epidermolysis bullosa

In brief

Topical gene therapy reduced wounds in 38 patients with inherited skin fragility

In this real-world observational study, beremagene geperpavec treatment was associated with smaller wound areas, less pain and itching, and shorter dressing times; most patients reported high satisfaction. Inflammation changes were mixed, and outcomes varied with factors including body mass index and other treatments, while antibody profiles did not predict response.

Journal
Journal of the European Academy of Dermatology and Venereology : JEADV (Q1)
Published
12 November 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Meropi Karakioulaki, Robin Frank, Oliver Storz, Hanning Yang, Anna Luisa Hartmann, Nora Hummel, et al.
PMID
43018251
DOI
10.1111/jdv.70839

Why clinicians should know about it

  • Picked for Dermatology (paper of the day, 18 November 2026): Real-world outcomes of topical gene therapy for epidermolysis bullosa

Abstract

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a severe inherited skin fragility disorder caused by mutations in COL7A1, leading to wounds, inflammation and impaired quality of life. Beremagene geperpavec (B-VEC) is the first approved topical gene therapy delivering functional COL7A1 via a modified HSV-1 vector, enabling local collagen VII expression and improved wound healing. OBJECTIVES: To evaluate the real-world, multidimensional long-term outcomes of B-VEC treatment in patients with DEB, including wound healing, systemic inflammation, (auto)-antibody profiles and patient-reported outcomes. METHODS: In this multicentre observational study, 38 patients with DEB received B-VEC treatment between January 2024 and June 2026. The primary endpoint was the change in wound surface area from baseline during B-VEC treatment. Secondary endpoints included changes in systemic inflammatory and haematological parameters [C-reactive protein (CRP), interleukin-6 (IL-6), serum amyloid A (SAA), leucocytes and haemoglobin (Hb)], (auto-)antibody profiles [anti-C7, BP180, BP230 and herpes simplex virus (HSV)-1/2 IgG], body mass index (BMI) and patient-reported outcomes, including pain, pruritus, treatment satisfaction and wound dressing time. RESULTS: B-VEC treatment was associated with a significant reduction in wound surface area across healing wounds. Patients having persistent wounds exhibited lower BMI and higher leucocyte counts and received systemic biologic therapies less frequently. Anti-BP180, BP230 and HSV-1/2 titres remained stable, while anti-C7 levels increased during treatment. IIF was negative in most patients and did not differ between groups. Systemic inflammation showed a mixed pattern, with reduced leucocyte counts and SAA levels, and slightly increased CRP and IL-6 under treatment. Hb and BMI increased during treatment. Most patients reported high treatment satisfaction and reduction in pain, pruritus and wound dressing time. CONCLUSIONS: B-VEC therapy provides clinically meaningful improvements in wound healing, patient-reported outcomes and selected systemic parameters in DEB. Treatment response is influenced by host factors such as BMI, systemic inflammation and concomitant therapies. Baseline (auto)-antibody profiles do not appear to predict treatment efficacy. Overall, B-VEC represents a significant advancement in the multidimensional management of DEB in real-world clinical practice.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.